Compugen Ltd. (CGEN) |
1.88 -0.02 (-1.05%) 04-18 16:00 |
Open: | 1.88 |
High: | 1.96 |
Low: | 1.8301 |
Volume: | 308,846 |
Market Cap: | 168(M) |
PE Ratio: | -8.95 |
Exchange: | NASDAQ Global Market |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 2.80 |
Resistance 1: | 2.43 |
Pivot price: | 2.24 |
Support 1: | 1.83 |
Support 2: | 1.52 |
52w High: | 3.03 |
52w Low: | 0.53 |
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
EPS | -0.210 |
Book Value | 0.740 |
PEG Ratio | 0.00 |
Gross Profit | 0.000 |
Profit Margin (%) | -56.05 |
Operating Margin (%) | 53.75 |
Return on Assets (ttm) | -7.5 |
Return on Equity (ttm) | -26.2 |
Sun, 14 Apr 2024
Compugen Ltd. (NASDAQ:CGEN) Sees Significant Increase in Short Interest - MarketBeat
Sat, 13 Apr 2024
Compugen (NASDAQ:CGEN) Stock Crosses Above Two Hundred Day Moving Average of $1.63 - Defense World
Wed, 13 Mar 2024
Should You Hold Compugen Ltd (CGEN) Stock Wednesday Morning? - InvestorsObserver
Fri, 08 Mar 2024
Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26% - Simply Wall St
Thu, 07 Mar 2024
Compugen Ltd. (NASDAQ:CGEN) Q4 2023 Earnings Call Transcript - Yahoo Finance
Tue, 05 Mar 2024
Compugen: Q4 Earnings Snapshot - Houston Chronicle
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |